PD-L1 Biomarkers
News and reporting on PD-L1 biomarkers.
Johns Hopkins researchers have developed a single-cell, multispectral imaging platform called AstroPath for precise pathological analysis of cancer specimens.
Breast Cancer Immunotherapy Response Markers Emerge From Single-Cell Sequencing Study
Researchers identified several pre-treatment markers that correlated with T-cell expansion and could be predictive of response to a PD1 inhibitor.
NanoView, Beth Israel Deaconess Medical Center Launch Immuno-Oncology Biomarker Study
The team will use NanoView's ExoView platform to characterize PD-L1 and other biomarkers carried by exosomes in plasma samples from patients undergoing therapy.
The companies will work with labs to improve payors' understanding of the costs of performing PD-L1 testing and the value it provides to patient care.
FDA Approves Merck's Keytruda, Agilent CDx in PD-L1-High Triple-Negative Breast Cancer
The agency approved Agilent/Dako's PD-L1 IHC test for identifying TNBC patients who are most likely to respond to Keytruda and chemo.